You're right again. The problem inlies with the efficacy of A2-73. If the MOA is unsupported, the data gathered certainly offers insight into how gut microbia relates to the effects of A2-73, but it would not demonstrate much beyond that. Precision medicine works if there is a positive effect to draw from, and that is certainly the hope here. It increases the likelihood of A2-73 being marketable if any positive effect is observed. If a positive effect is observed in a smaller percentage of a large population AND the effect can be linked to some/any markers, then the precision medicine approach has worked. If the effect cannot be linked, there is no benefit. The governments and investors would have to determine how much they would want to spend at that point to find the link for the relative size of the sample population. The greater hope is that there is a positive effect with markers identified and those markers provide insight into other approaches to treat alzheimers.
Worst case scenario is that there is no benefit observed.
News 
Market Data 
Discover 
